Apogee Therapeutics (NASDAQ: APGE) CFO logs stock sales and option grant

Rhea-AI Filing Summary

Apogee Therapeutics’ chief financial officer Jane Henderson reported stock sales and a new stock option grant. On January 2, 2026, she sold 1,920 shares of common stock at a weighted average price of $74.13 and 4,080 shares at a weighted average price of $75.20, under a Rule 10b5-1 trading plan adopted on September 27, 2024. On January 6, 2026, she sold an additional 2,000 shares at $80.00, leaving her with 185,371 common shares held directly.

Separately, on January 2, 2026, she received a stock option to purchase 83,690 shares of common stock at an exercise price of $75.78 per share. This option vests in 48 equal monthly installments over four years from the grant date, subject to her continued service, and is scheduled to expire on January 2, 2036.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Henderson Jane

(Last) (First) (Middle)

C/O APOGEE THERAPEUTICS, INC.

221 CRESCENT ST., BLDG. 17, STE. 102B

(Street)

WALTHAM MA 02453

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Apogee Therapeutics, Inc. [ APGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/02/2026		S(1)		1,920	D	$74.13(2)	191,451	D
Common Stock	01/02/2026		S(1)		4,080	D	$75.2(3)	187,371	D
Common Stock	01/06/2026		S(1)		2,000	D	$80	185,371	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$75.78	01/02/2026		A		83,690		(4)	01/02/2036	Common Stock	83,690	$0.00	83,690	D

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2024.

2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $73.67 to $74.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $74.73 to $75.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

4. This option represents the right to purchase 83,690 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments over a four-year period from the date of grant, subject to the Reporting Person's continued service to the Issuer.

	/s/ Matthew Batters, as attorney-in-fact for Jane Pritchett Henderson	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Apogee Therapeutics (APGE) report for its CFO?

Jane Henderson, Apogee Therapeutics’ chief financial officer, reported multiple stock sales and a new stock option grant. She sold shares of common stock on January 2, 2026 and January 6, 2026, and received a stock option for 83,690 shares on January 2, 2026.

How many Apogee Therapeutics (APGE) shares did the CFO sell and at what prices?

On January 2, 2026, the CFO sold 1,920 shares at a weighted average price of $74.13 and 4,080 shares at a weighted average price of $75.20. On January 6, 2026, she sold an additional 2,000 shares at $80.00 per share.

Was the Apogee Therapeutics (APGE) CFO’s stock sale under a Rule 10b5-1 trading plan?

Yes. The filing states that one of the reported transactions was executed under a Rule 10b5-1 trading plan that was adopted on September 27, 2024, which pre‑sets trading instructions in advance.

What stock option grant did the Apogee Therapeutics (APGE) CFO receive?

On January 2, 2026, the CFO received a stock option covering 83,690 shares of Apogee Therapeutics common stock with an exercise price of $75.78 per share. The option is held directly.

How does the CFO’s new stock option in Apogee Therapeutics (APGE) vest?

The stock option for 83,690 shares vests in 48 equal monthly installments over four years from the January 2, 2026 grant date, subject to the CFO’s continued service to the company. It is scheduled to expire on January 2, 2036.

How many Apogee Therapeutics (APGE) shares does the CFO own after these transactions?

After the reported sales, the CFO beneficially owns 185,371 shares of Apogee Therapeutics common stock directly, according to the filing.

What is the role of Jane Henderson at Apogee Therapeutics (APGE)?

Jane Henderson is identified in the filing as an officer of Apogee Therapeutics, serving as the company’s Chief Financial Officer.